<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105598</url>
  </required_header>
  <id_info>
    <org_study_id>ETC-1002-002</org_study_id>
    <nct_id>NCT01105598</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia</brief_title>
  <official_title>A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ETC-1002 in Subjects With Mild Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability,
      pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with
      mild dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety and tolerability using adverse event reports, physical exams, vitals signs, ECGs, and clinical lab values</measure>
    <time_frame>14 or 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of pharmacokinetic parameters and percent change from baseline in pharmacodynamic endpoints</measure>
    <time_frame>14 or 28 days</time_frame>
    <description>Pharmacodynamic endpoints include total cholesterol, low density lipoprotein-cholesterol (LDL-C), triglycerides (TG), high density lipoprotein-cholesterol (HDL-C) and free fatty acids (FFA)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Mild Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free-living subjects (18 active/6 placebo) with mild dyslipidemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETC-1002 or placebo</intervention_name>
    <description>ETC-1002 (ascending dose), daily for 14 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETC-1002 or placebo</intervention_name>
    <description>ETC-1002 (optimized dose), daily for 28 days</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETC-1002 or placebo</intervention_name>
    <description>ETC-1002 (20 mg), daily for 14 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects of non-child bearing potential as determined by
             medical history, physical examination, vital signs, ECG, and clinical laboratory
             measurements

          -  Fasting low density lipoprotein-cholesterol (LDL-C) of 100-160 mg/dL

          -  Fasting triglycerides (TG) of 100-350 mg/dL (Cohort 5 only)

          -  Body Mass Index (BMI) of 18-32 kg/m2 (Cohort 1 to 4 only) or 18-36 (Cohort 5 only) and
             body weight &gt;50 kg

        Exclusion Criteria:

          -  Clinically significant disease that requires a physician's care and/or would interfere
             with study evaluations

          -  Alanine aminotransferase (ALT) or aspartate amino transferase (AST) &gt;1.2 x ULN; serum
             creatinine &gt;ULN; hemoglobin &lt;12.0 g/dL; other clinical lab tests (with the exception
             of ALT, AST, serum creatinine and hemoglobin) outside normal or protocol specified
             limits that are determined by the Investigator to be clinically significant

          -  Use of tobacco or tobacco products

          -  Use of any prescription or nonprescription drugs, vitamins, or dietary supplements
             within 14 days prior to randomization with the exception of lipid regulating drugs or
             supplements containing niacin &gt;500 mg/day or fish oil which will not have been used
             for 3 months prior to randomization

          -  Other exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jasper Clinic, Inc.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>November 16, 2010</last_update_submitted>
  <last_update_submitted_qc>November 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Esperion Therapeutics</name_title>
    <organization>Esperion Therapeutics</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

